Agathe Bédard

Agathe Bédard

Auto-generated profile, based on publicly available information

Agathe Bédard

Charles River Laboratories Montreal ULC , Senneville, QC H9X 3R3

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2021 in Toxicologic Pathology
Verified
Journal Article
Closed access
PDF file
ABAgathe Bédard
Agathe Bédard
TWThomas Westerling-Bui
Thomas Westerling-Bui
AZAleksandra Zuraw
Aleksandra Zuraw
Inflammatory bowel disease (IBD) is a complex disease which leads to life-threatening complications and decreased quality of life. The dextran sulfate sodium (DSS) colitis model in mice is known for rapid screening of candidate compounds. Efficacy assessment in this model relies partly on microscopic semiquantitative scoring, which is time-consuming and subjective. We hypothesized that deep learning artificial intelligence (AI) could be used to identify acute inflammation in H&E-stained sections in a consistent and quantitative manner. Training sets were established using ×20 whole slide images of the entire colon. Supervised training of a Convolutional Neural Network (CNN) was performed using a commercial AI platform to detect the entire colon tissue, the muscle and mucosa layers, and 2 categories within the mucosa (normal and acute inflammation E1). The training sets included slides of naive, vehicle-DSS and cyclosporine A-DSS mice. The trained CNN was able to segment, with a high level of concordance, the different tissue compartments in the 3 groups of mice. The segmented areas were used to determine the ratio of E1-affected mucosa to total mucosa. This proof-of-concept work shows promise to increase efficiency and decrease variability of microscopic scoring of DSS colitis when screening candidate compounds for IBD.

1 April 2019 in Regulatory Toxicology and Pharmacology
Verified
Journal Article
Open access
MBMartin Billger
Martin Billger
JKJason Kirk
Jason Kirk
JCJane Chang
Jane Chang
ABAgathe Bédard
Agathe Bédard
BABassem Attalla
Bassem Attalla
MSMagnus Söderberg
Magnus Söderberg
Dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, is indicated to improve glycaemic control in adults of type 2 diabetes. In nonclinical studies, dapagliflozin was neither genotoxic nor carcinogenic. However, in some clinical studies, an increased incidence of bladder cancer was observed in the dapagliflozin group vs. the placebo. Therefore, this study was undertaken to determine if dapagliflozin can act as a promoter in a 2-stage bladder cancer model in rats induced with N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN). Rats given BBN (100 or 400 mg/kg, po) twice weekly for 6 weeks in Phase 1 were assigned in Phase 2 to receive daily dose of vehicle, dapagliflozin (0.5 mg/kg, po) or uracil (positive control, 3% in diet) from weeks 8-34. All bladders were evaluated by histopathology. Verifying the validity of the model, uracil increased the incidence of bladder cancer, while dapagliflozin had no effect on the incidence or invasiveness of transitional cell carcinoma. The exposure of dapagliflozin at 0.5 mg/kg/day in rats was 7 times the clinical exposure at maximal therapeutic dose (10 mg). In conclusion, dapagliflozin does not act as promoter or progressor of bladder cancer in a validated bladder cancer model in rats.

Verified
Journal Article
Open access
PDF file
COColombe Otis
Colombe Otis
EBEmilie Bouet
Emilie Bouet
SKSokhna Keita-Alassane
Sokhna Keita-Alassane
MFMarilyn Frézier
Marilyn Frézier
ADAliénor Delsart
Aliénor Delsart
ETEric Troncy
Eric Troncy
Validating animal pain models is crucial to enhancing translational research and response to pharmacological treatment. This study investigated the effects of a calibrated slight exercise protocol alone or combined with multimodal analgesia on sensory sensitivity, neuroproteomics, and joint structural components in the MI-RAT model. Joint instability was induced surgically on day (D) 0 in female rats (N = 48) distributed into sedentary–placebo, exercise–placebo, sedentary–positive analgesic (PA), and exercise–PA groups. Daily analgesic treatment (D3–D56) included pregabalin and carprofen. Quantitative sensory testing was achieved temporally (D–1, D7, D21, D56), while cartilage alteration (modified Mankin’s score (mMs)) and targeted spinal pain neuropeptide were quantified upon sacrifice. Compared with the sedentary–placebo (presenting allodynia from D7), the exercise–placebo group showed an increase in sensitivity threshold (p < 0.04 on D7, D21, and D56). PA treatment was efficient on D56 (p = 0.001) and presented a synergic anti-allodynic effect with exercise from D21 to D56 (p < 0.0001). Histological assessment demonstrated a detrimental influence of exercise (mMs = 33.3%) compared with sedentary counterparts (mMs = 12.0%; p < 0.001), with more mature transformations. Spinal neuropeptide concentration was correlated with sensory sensitization and modulation sites (inflammation and endogenous inhibitory control) of the forced mobility effect. The surgical MI-RAT OA model coupled with calibrated slight exercise demonstrated face and predictive validity, an assurance of higher clinical translatability.

6 July 2023
Verified
Book Chapter
Open access
RARoger Alison
Roger Alison
JBJames E. Baily
James E. Baily
ABAlys E. Bradley
Alys E. Bradley
ABAgathe Bédard
Agathe Bédard
MCMaurice Cary
Maurice Cary
JWJayne A. Wright
Jayne A. Wright

21 July 2026 in JBMR Plus
Verified
Journal Article
Open access
ABAgathe Bédard
Agathe Bédard
DDDenise Dwyer
Denise Dwyer
MFMelanie Felx
Melanie Felx
MGMartin Guillot
Martin Guillot
ABAmy Bourdeau
Amy Bourdeau
SFSerge Ferrari
Serge Ferrari
To explore how preceding treatment with a bisphosphonate (BP) and/or OPG-Fc, a RANKL inhibitor, affects early bone formation (BF) response to sclerostin antibody (Scl-Ab) in vertebral cancellous and cortical bone, we treated ovariectomized rats with various sequences of vehicle (Veh), OPG-Fc, and alendronate (Aln) or zoledronic acid (ZOL) in cycle 1 (0-12 wk) or cycle 2 (12-18 wk) before administering Scl-Ab in cycle 3 (18-24 wk). Treatment sequences included Veh/Veh/Scl-Ab (treatment naïve), OPG-Fc/OPG-Fc/Scl-Ab, OPG-Fc/ZOL/Scl-Ab, Aln/OPG-Fc/Scl-Ab, and OPG-Fc/OPG-Fc_Veh/Scl-Ab (4-wk treatment-free period preceding Scl-Ab). DXA scans and serum bone turnover markers were assessed. Cancellous and endocortical histomorphometric endpoints were quantified at weeks 18, 20, and 24. With Veh/Veh/Scl-Ab, anticipated bone responses to Scl-Ab were observed. From week 18 to week 24, Scl-Ab-mediated bone mass accrual was blunted with preceding antiresorptive sequences. In groups where OPG-Fc immediately preceded Scl-Ab, BF suppression was marked at week 20 with limited modeling-based bone formation (MBBF). In contrast, when ZOL was interposed between OPG-Fc and Scl-Ab, MBBF was modestly reduced at week 20. By week 24, BF surfaces were generally similar in all groups; the contribution of MBBF and remodeling-based bone formation (RBBF) differed. In contrast to other antiresorptive sequences, in OPG-Fc/OPG-Fc_Veh/Scl-Ab, RBBF was also a significant contributor to bone forming surfaces, reflecting a rebound in resorption and remodeling. With the other antiresorptive sequences, MBBF was the major contributor to BF, consistent with prolonged suppression of remodeling at week 24. All prior antiresorptive sequences blunted Scl-Ab effects on early BF. BP exposure (before or after OPG-Fc) improved cumulative effects across all cycles on bone mass compared with OPG-Fc alone. Interposing ZOL between OPG-Fc and Scl-Ab improved the early BF response to Scl-Ab.

6 May 2025
Verified
Book Chapter
Closed access
PDF file
KGKathryn E. Gropp
Kathryn E. Gropp
ABAgathe Bédard
Agathe Bédard
SFStacey Fossey
Stacey Fossey
DHD. Greg Hall
D. Greg Hall
RSRyan M. Schafbuch
Ryan M. Schafbuch
The musculoskeletal system, composed of bones, joints, and muscles, is a dynamic and complex system responsible for locomotion, mechanical support, and protection from trauma for internal organs, hematopoiesis, calcium and inorganic phosphorus metabolism, and endocrine regulation. As teeth share with bone the specificity of being a mineralized and dynamic tissue, toxic changes are often commonly encountered in both tissues simultaneously. As such, functional anatomy and physiology, as well as induced and spontaneous lesions noted in musculoskeletal system and teeth, will be discussed together in this chapter. In addition, considerations for adversity determination and translatability of findings will be presented, to provide a reference for toxicopathologists and toxicologists. <!----> <!----> <!----> <!---->